193 related articles for article (PubMed ID: 20209387)
1. Cucurbitacin: ancient compound shedding new light on cancer treatment.
Lee DH; Iwanski GB; Thoennissen NH
ScientificWorldJournal; 2010 Mar; 10():413-8. PubMed ID: 20209387
[TBL] [Abstract][Full Text] [Related]
2. Potential of cucurbitacin as an anticancer drug.
Li Y; Li Y; Yao Y; Li H; Gao C; Sun C; Zhuang J
Biomed Pharmacother; 2023 Dec; 168():115707. PubMed ID: 37862969
[TBL] [Abstract][Full Text] [Related]
3. Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity.
Cai Y; Fang X; He C; Li P; Xiao F; Wang Y; Chen M
Am J Chin Med; 2015; 43(7):1331-50. PubMed ID: 26503558
[TBL] [Abstract][Full Text] [Related]
4. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer.
Chen X; Bao J; Guo J; Ding Q; Lu J; Huang M; Wang Y
Anticancer Drugs; 2012 Sep; 23(8):777-87. PubMed ID: 22561419
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement.
Kumar A; Sharma B; Sharma U; Parashar G; Parashar NC; Rani I; Ramniwas S; Kaur S; Haque S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1867-1878. PubMed ID: 37010571
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin mediated regulation of deregulated oncogenic signaling cascades and non-coding RNAs in different cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways.
Lin X; Farooqi AA
Semin Cancer Biol; 2021 Aug; 73():302-309. PubMed ID: 33152487
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway.
Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT
Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma.
Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F
Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells.
Zhang J; Song Y; Liang Y; Zou H; Zuo P; Yan M; Jing S; Li T; Wang Y; Li D; Zhang T; Wei Z
Food Chem Toxicol; 2019 Oct; 132():110654. PubMed ID: 31265865
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
11. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds.
Ríos JL; Andújar I; Escandell JM; Giner RM; Recio MC
Curr Pharm Des; 2012; 18(12):1663-76. PubMed ID: 22443631
[TBL] [Abstract][Full Text] [Related]
13. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors.
Molavi O; Ma Z; Mahmud A; Alshamsan A; Samuel J; Lai R; Kwon GS; Lavasanifar A
Int J Pharm; 2008 Jan; 347(1-2):118-27. PubMed ID: 17681440
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.
Silva IT; Geller FC; Persich L; Dudek SE; Lang KL; Caro MS; Durán FJ; Schenkel EP; Ludwig S; Simões CM
Invest New Drugs; 2016 Apr; 34(2):139-48. PubMed ID: 26780083
[TBL] [Abstract][Full Text] [Related]
15. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.
Ahmed MS; Kopel LC; Halaweish FT
ChemMedChem; 2014 Jul; 9(7):1361-7. PubMed ID: 24682977
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins.
Chatzisideri T; Dalezis P; Leonidis G; Bousis S; Trafalis D; Bianchini F; Sarli V
Future Med Chem; 2021 May; 13(10):877-895. PubMed ID: 33858195
[TBL] [Abstract][Full Text] [Related]
17. The cucurbitacins E, D and I: investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver.
Abbas S; Vincourt JB; Habib L; Netter P; Greige-Gerges H; Magdalou J
Toxicol Lett; 2013 Feb; 216(2-3):189-99. PubMed ID: 23194827
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells.
Brouwer IJ; Out-Luiting JJ; Vermeer MH; Tensen CP
Biochem Biophys Rep; 2020 Dec; 24():100832. PubMed ID: 33102814
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms.
Varela C; Melim C; Neves BG; Sharifi-Rad J; Calina D; Mamurova A; Cabral C
J Transl Med; 2022 Dec; 20(1):630. PubMed ID: 36585670
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin IIa: A review of phytochemistry and pharmacology.
Zeng Y; Wang J; Huang Q; Ren Y; Li T; Zhang X; Yao R; Sun J
Phytother Res; 2021 Aug; 35(8):4155-4170. PubMed ID: 33724593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
